Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: Implications for tumor immunotherapy

Journal of Experimental Medicine

Volumn 191, Issue 7, 2000, Pages 1221-1231

  Colella, Teresa A ^a   Bullock, Timothy N J ^a   Russell, Liane B ^b   Mullins, David W ^a   Overwijk, Willem W ^c   Luckey, Chance John ^a   Pierce, Richard A ^a   Restifo, Nicholas P ^c   Engelhard, Victor H ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocytes; Immunotherapy; MHC class I; Self tolerance; Tyrosinase

Indexed keywords

MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SEQUENCE HOMOLOGY; VACCINIA VIRUS; VITILIGO;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CROSS REACTIONS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOCYTES; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MONOPHENOL MONOOXYGENASE; PEPTIDES; SELF TOLERANCE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034599497     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.7.1221     Document Type: Article

References (66)

1. Slingluff, C.L, Jr., A.L. Cox, R.A. Henderson, D.F. Hunt, and V.H. Engelhard. 1993. Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes. J. Immunol. 150:2955-2963.
2. Cox, A.L., J.C. Skipper, Y. Chen, R.A. Henderson, T.L. Darrow, J. Shabanowitz, V.H. Engelhard, D.F. Hunt, and C.L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 264:716-719.
3. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P.F. Robbins, A. Sette, E. Appella, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961-3968.
4. + cytotoxic T lymphocytes. J. Exp. Med. 181:363-368.
5. Wolfel, T., E. Klehmann, C. Muller, K.H. Schutt, K.H. Meyer zum Büschenfelde, and A. Knuth. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility antigen A2 as a restriction element for three different antigens. J. Exp. Med. 170:797-810.
6. Darrow, T.L., C.L. Slingluff, Jr., and H.F. Seigler. 1989. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. J. Immunol. 142:3329-3335.
7. Hom, S.S., S.L. Topalian, T. Simonis, M. Mancini, and S.A. Rosenberg. 1991. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J. Immunother. 10:153-164.
8. Storkus, W.J., H.J. Zeh III, M.J. Maeurer, R.D. Salter, and M.T. Lotze. 1993. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J. Immunol. 151:3719-3727.
9. Celis, E., V. Tsai, C. Crimi, R. DeMars, P.A. Wentworth, R.W. Chesnut, H.M. Grey, A. Sette, and H.M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105-2109.
10. van der Bruggen, P., J. Bastin, T. Gajewski, P.G. Coulie, P. Boel, C. de Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur. J. Immunol. 24:3038-3043.
11. Boel, P., C. Wildmann, M.L. Sensi, R. Brasseur, J.C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:167-175.
12. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182:689-698.
13. Wolfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K.H.M. zum Büschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24: 759-764.
14. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489-495.
15. Skipper, J.C.A., R.C. Hendrickson, P.H. Gulden, V. Brichard, A. Van Pel, Y. Chen, J. Shabanowitz, T. Wolfel, C.L. Slingluff, Jr., T. Boon, et al. 1996. An HLA-A2 restricted tyrosinase antigen on melanoma cells results from post-translational modification and suggests a novel processing pathway for membrane proteins. J. Exp. Med. 183:527-534.
16. Bakker, A.B.H., M.W. Schreurs, A.J. de Boer, Y. Kawakami, S.A. Rosenberg, G.J. Adema, and C.G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005-1009.
17. Wang, R.F., P.F. Robbins, Y. Kawakami, X.Q. Kang, and S.A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181:799-804.
18. Wang, R.F., E. Appella, Y. Kawakami, X. Kang, and S.A. Rosenberg. 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184:2207-2216.
19. Yannelli, J.R., S. McConnell, L. Parker, M. Nishimura, P. Robbins, J. Yang, M.E. Gamil, and Y. Kawakami. 1996. Melanoma tumor-infiltrating lymphocytes derived from four distinct anatomic sites obtained from a single patient: comparison of functional reactivity and melanoma antigen recognition. J. Immunother. 18:263-271.
20. Romero, P., P.R. Dunbar, D. Valmori, M. Pittet, G.S. Ogg, D. Rimoldi, J.L. Chen, D. Lienard, J.C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class 1 major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641-1650.
21. Jager, E., M. Ringhoffer, J. Karbach, M. Arnand, F. Oesch, and A. Knuth. 1996. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66:470-476.
22. de Vries, T.J., A. Fourkour, T. Wobbes, G. Verkroost, D.J. Ruiter, and G.N. van Muijen. 1997. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 57:3223-3229.
23. Slingluff, C.L., Jr., T.A. Colella, L. Thompson, D.D. Graham, J.C.A. Skipper, J.A. Caldwell, L. Brinkerhoff, D.J. Kittlesen, D.H. Deacon, C. Oei, et al. 2000. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol. Immunother. 48:661-672.
24. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
25. Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
26. Duhra, P., and A. Ilchyshyn. 1991. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin. Exp. Dermatol. 16:303-305.
27. Rosenberg, S.A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today. 18:175-182.
28. Song, Y.H. 1997. Why tyrosinase for treatment of melanoma. Lancet. 350:82-83.
29. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg, 1994. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.
30. Anichini, A., C. Maccali, R. Mortarini, S. Salvi, A. Mazzocchi, P. Squarcina, M. Herlyn, and G. Parmiani. 1993. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 170:797-810.
31. Kawakami, Y., S. Eliyahu, C.H. Delgaldo, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994. Cloning of the gene for a shared melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA. 91:3515-3519.
32. Anichini, A., R. Mortarini, C. Maccali, P. Squarcina, K. Fleischhauer, L. Mascheroni, and G. Parmiani. 1996. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol. 156:208-217.
33. Ogg, G.S., D.P. Rod, P. Romero, J.L. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med. 188:1203-1208.
34. Rimchik, E.M., J.P. Stoye, W.N. Frankel, J. Coffin, B.S. Kwon, and L.B. Russell. 1993. Molecular analysis of viable spontaneous and radiation-induced albino (c)-locus mutations in the mouse. Mutat. Res. 286:199-207.
35. Newberg, M.H., J.P. Ridge, D.R. Vining, R.D. Salter, and V.H. Engelhard. 1992. Species specificity in the interaction of CD8 with the α3 domain of MHC class I molecules. J. Immunol. 149:136-142.
36. Beier, D.C., J.H. Cox, D.R. Vinnig, P. Cresswell, and V.H. Engelhard. 1994. Association of human class I MHC alleles with the adenovirus E3/19K protein. J. Immunol. 152:3862-3872.
37. Engelhard, V.H. J.R. Yannelli, G.A. Evans, S.F. Walk, and M.J. Holterman. 1985. Construction of novel class 1 histocompatibility antigens by interspecies exon shuffling. J. Immunol. 134:4218-4225.
38. Mosse, C.A., L. Meadows, C.J. Luckey, D.J. Kittlesen, E.L. Huczko, C.L. Slingluff, Jr., J. Shabanowitz, D.F. Hunt, and V.H. Engelhard. 1998. The class I antigen processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187:37-48.
39. Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
40. Chen, Y., J. Sidney, S. Southwood, A.L. Cox, K. Sakaguchi, R. Henderson, E. Appella, D.F. Hunt, A. Sette, and V.H. Engelhard. 1994. Naturally processed peptides longer than nine amino acid residues bind to the class 1 MHC molecule HLA-A2.1 with high affinity and in different conformations. J. Immunol. 152:2874-2881.
41. Newberg, M.H., D.H. Smith, S.B. Haertel, D.R. Vining, E. Lacy, and V.H. Engelhard. 1996. Importance of MHC class I α2 and α3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 156:2473-2480.
42. Rikke, B.A., D.K. Johnson, and T.E. Johnson. 1997. Murine albino-deletion complex: high-resolution microsatellite map and genetically anchored YAC framework map. Genetics. 147:787-799.
43. Engelhard, V.H. 1994. Structure of peptides associated with MHC class 1 molecules. Curr. Opin. Immunol. 6:13-23.
44. Bullock, T.N.J., T.A. Colella, and V.H. Engelhard. 2000. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. 164:2354-2361.
45. Bloom, M.B., D. Perry-Lalley, P.F. Robbins, Y. Li, M. el-Gamil, S.A. Rosenberg, and J.C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453-459.
46. Kluppel, M., F. Beermann, S. Ruppert, E. Schmid, E. Hummler, and G. Schutz. 1991. The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. Proc. Natl. Acad. Sci. USA. 88: 3777-3781.
47. Gaugler, B., N. Brouwenstijn, V. Vantomme, J.P. Szikora, C.W. van der Spek, J.J. Patard, T. Boon, P. Schrier, and B. Van den Eynde. 1996. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics, 44:323-330.
48. Tief, K., A. Schmidt, A. Aguzzi, and F. Beermann. 1996. Tyrosinase is a new marker for cell populations in the mouse neural tube. Dev. Dyn. 205:445-456.
49. Tief, K., M. Hahne, A. Schmidt, and F. Beerman. 1996. Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain. Eur. J. Biochem. 241:12-16.
50. Battyani, Z., L. Xerri, J. Hassoun, J.J. Bonerandi, and J.J. Grob. 1993. Tyrosinase gene expression in human tissues. Pigment Cell Res. 6:400-405.
51. Heath, W.K., C. Kurts, J.F.A.P. Miller, and F.R. Carbone, 1998. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 187:1549-1553.
52. + T cells. J. Exp. Med. 185:239-245.
53. Kurts, C., W.R. Heath, F.R. Carbone, J. Allison, J.F.A.P. Miller, and H. Kosaka. 1999. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184:923-930.
54. Morgan, D.J., H.T. Kreuwel, S. Fleck, H.I. Levitsky, D.M. Pardoll, and L. A. Sherman. 1998. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not antoimmunity. J. Immunol. 160:643-651.
55. Morgan, D.J., H.T.C. Kreuwel, and L.A. Sherman. 1999. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J. Immunol. 163:723-727.
56. Schonrich, G., F. Momburg, M. Malissen, A.M. Schmitt-Verhulst, B. Malissen, G.J. Hammerling, and B. Arnold. 1992. Distinct mechanisms of extrathymic T cell tolerance due to differential expression of self antigen. Int. Immunol. 4:581-590.
57. Evavold, B.D., J. Sloan-Lancaster, B.L. Hsu, and P.M. Allen. 1993. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. J. Immunol. 150: 3131-3140.
58. Jameson, S.C., and M.J. Bevan. 1995. T cell receptor antagonists and partial agonists. Immunity. 2:1-11.
59. Hemmer, B., I. Stefanova, M. Vergelli, R.N. Germain, and R. Martin. 1998. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J. Immunol. 160:5807-5814.
60. Rogers, P.R., H.M. Grey, and M. Croft. 1998. Modulation of naive T cell activation with altered peptide ligands: the nature of the peptide and presentation in the context of co-stimulation are critical for a sustained response. J. Immunol. 160:3698-3704.
61. Hollsberg, P., W.E. Weber, F. Dangond, V. Batra, A. Sette, and D.A. Hafler. 1995. Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. Proc. Natl. Acad. Sci. USA. 92:4036-4040.
62. Alferink, J., A. Tafuri, D. Vestweber, R. Hallmann, G.J. Hammerling, and B. Arnold. 1998. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science. 282:1338-1341.
63. Hara, I., Y. Takechi, and A.N. Houghton. 1995. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med. 182:1609-1614.
64. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasaradhi, and A.N. Houghton. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA. 93:14809-14814.
65. + T lymphocytes. Proc. Natl. Acad. Sci. USA. 96:2982-2987.
66. van Elsas, A.H.A.A., and J.P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmemation. J. Exp. Med. 190:355-366.